Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-08-16
2011-08-16
Kolker, Daniel E (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07998684
ABSTRACT:
A compound that promotes the ubiquitination of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or a partial peptide thereof or a salt thereof, or a salt thereof, a compound that promotes the degradation, by proteasome, of the protein or a partial peptide thereof or a salt thereof, or a salt thereof, and the like can be used as, for example, prophylactic/therapeutic agents for neurodegenerative disease. Also, a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or a partial peptide thereof or a salt thereof and the like are useful for screening for a compound having prophylactic/therapeutic action on neurodegenerative disease and the like or a salt thereof.
REFERENCES:
patent: 5187153 (1993-02-01), Cordell et al.
patent: 6720181 (2004-04-01), Chiaur et al.
patent: 2003/0092603 (2003-05-01), Mundy et al.
patent: 1 428 891 (2004-06-01), None
patent: 00/75184 (2000-12-01), None
patent: 02/100333 (2002-12-01), None
patent: 03/023405 (2003-03-01), None
Janelle Nunan et al., “The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from γ-secretase”, Eur. J. Biochem., vol. 268, pp. 5329-5336 (2001).
Luisa Gregori et al., “Ubiquitin-Mediated Degradative Pathway Degrades the Extra Cellular But Not the Intracellular Form of Amyloid β-Protein Precursor”, Biochemical and Biophysical Research Communications, vol. 203, No. 3, pp. 1731-1738 (1994).
Gennady P. Ilyin et al., “cDNA Cloning and Expression Analysis of New Members of the Mamalian F-Box Protein Family”, Genomics, vol. 67, pp. 40-47 (2000).
Eric M. Blalock et al.,“Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses”, PNAS, vol. 101, No. 7, pp. 2173-2178 (2004).
Fred W. Van Leeuwen et al., “Frameshift Mutants of β Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients”, Science, vol. 279, pp. 242-247 (1998).
European Patent Search Report issued on Jun. 29, 2009 for the corresponding European Patent Application No. 06713546.
Nunan Janelle et al.,“Proteasome-mediated degradation of the C-terminus of the Alzheimer's Disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein.”, Journal of Neuroscience Research, vol. 74, No. 3, Nov. 1, 2003, pp. 378-385, XP002532260.
Winston et al.,“A family of mammalian F-box proteins”, Current Biology, Current Science, GB, vol. 9, No. 20, Oct. 21, 1999, pp. 1180-1182, XP005106516.
De Vrij F M S et al.,“Protein quality control in Alzheimer's disease by the ubiquitin proteasome system”, Progress in Neurobiology, Pergamon Press, GB, vol. 74, No. 5, Dec. 1, 2004, pp. 249-270, XP004668681.
Horiguchi Takashi
Shintani Yasushi
Watanabe Tomomichi
Emch Gregory S
Kolker Daniel E
Takeda Pharmaceutical Company Limited
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Screening method for an agent for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening method for an agent for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening method for an agent for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2676367